How do you manage a FIGO stage IB dedifferentiated endometrial carcinoma that is MMR deficient and p53 wt?

Aggressive disease.

Favor chemo plus IO (MMR-d) (Van Gorp et al., PMID 39284383) followed by EBRT.

If this patient was adequately staged, I would proceed with a CT scan to try to find measurable disease. If there was measurable disease, I would give them chemo+IO per GY018 or RUBY. If there was no measurable disease, I would look harder for some and still if I couldn't find it I would give them p...

Agree that from a systemic therapy perspective, chemo/IO is appropriate, regardless of whether there is residual disease or not, for a stage IB high-risk histology cancer that is dMMR, per KEYNOTE-B21 as mentioned by Dr. @Dr. First Last.

In terms of radiation, I would have shared decision making in r...